Currently out of the existing stock ratings of Jonathan Wolleben, 341 are a BUY (99.71%), 1 are a HOLD (0.29%).
Analyst Jonathan Wolleben, has had 37.65% of price targets met with an average potential upside of 48.95%, reached in 200 days on average.
Jonathan Wolleben has documented 663 price targets and ratings displayed on 24 stocks. The coverage was on Healthcare, Communication Services sectors.
Most recent stock forecast was given on MIRM, Mirum Pharmaceuticals at 04-Nov-2026.
Analyst best performing recommendations are on DBVT (DBV TECHNOLOGIES).
The best stock recommendation documented was for RYTM (RHYTHM PHARMACEUTICALS) on 7/2/2025. The price target of $84 was fulfilled within 7 days with a profit of $17.08 (25.52%), with a performance score of 36.46.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 28-Jul-2020
$11
$9.39 (583.23%)
$11
5 months 16 days ago
(02-Jun-2026)
0/19 (0%)
$8.1 (279.31%)
Buy Since 02-Jun-2021
$20
$18.39 (1142.24%)
$17.33
5 months 30 days ago
(19-May-2026)
0/24 (0%)
$17.26 (629.93%)
Buy Since 29-Dec-2021
$28
$26.39 (1639.13%)
$35
7 months 22 days ago
(27-Mar-2026)
0/5 (0%)
$24.98 (827.15%)
Buy Since 25-Sep-2020
$18
$20
1 years 3 months 5 days ago
(13-Aug-2025)
3/14 (21.43%)
$14.26 (381.28%)
272
Buy Since 12-Nov-2024
$24
$26
1 years 3 months 5 days ago
(13-Aug-2025)
0/3 (0%)
$20.26 (541.71%)
Which stock is Jonathan Wolleben most bullish on?
Which stock is Jonathan Wolleben most reserved on?